EIT Pharma

EIT Pharma

EIT Pharma is a biotechnology company focused on developing therapies for infectious diseases. The company is advancing lonafarnib, an investigational oral therapy for chronic hepatitis D, which has the potential to improve treatment accessibility and quality of life for patients. This funding round will support FDA review activities and further development of their infectious disease pipeline.

Total raised
$35M
tracked to date
Latest round
Series A
Aug 31, 2026
Known investors
3
led by Propel Bio Partners
Press coverage
2
outlets tracked

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. 1
    $35MSeries AAug 31, 2026

    Led by Propel Bio Partners

    Announcement ↗

Founder

Leen Kawas
Leen Kawas
CEO

Investors in EIT Pharma

Backers from this company's tracked funding rounds.

  • PPropel Bio PartnersLead investorVC firm
  • GGood VenturesVC firm
  • AArrowtownVC firm

EIT Pharma in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile